Trials / Not Yet Recruiting
Not Yet RecruitingNCT07449780
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
A Randomized, Open-Label, Multicenter, Phase I/III Clinical Study to Evaluate the Pharmacokinetics, Efficacy and Safety of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Regimen Versus AK104 (IV) in Combination With XELOX Regimen as First-Line Treatment for Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 422 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK104(SC) | AK104:subcutaneous injection |
| DRUG | AK104(IV) | AK104:intravenous |
| DRUG | Capecitabine | oral |
| DRUG | Oxaliplatin injection | intravenous |
Timeline
- Start date
- 2026-03-31
- Primary completion
- 2027-11-17
- Completion
- 2028-02-15
- First posted
- 2026-03-04
- Last updated
- 2026-03-04
Source: ClinicalTrials.gov record NCT07449780. Inclusion in this directory is not an endorsement.